A Novel Homozygous Truncating GNAT1 Mutation Implicated in Retinal Degeneration
Overview
Affiliations
Background: The GNAT1 gene encodes the α subunit of the rod transducin protein, a key element in the rod phototransduction cascade. Variants in GNAT1 have been implicated in stationary night-blindness in the past, but unlike other proteins in the same pathway, it has not previously been implicated in retinitis pigmentosa.
Methods: A panel of 182 retinopathy-associated genes was sequenced to locate disease-causing mutations in patients with inherited retinopathies.
Results: Sequencing revealed a novel homozygous truncating mutation in the GNAT1 gene in a patient with significant pigmentary disturbance and constriction of visual fields, a presentation consistent with retinitis pigmentosa. This is the first report of a patient homozygous for a complete loss-of-function GNAT1 mutation. The clinical data from this patient provide definitive evidence of retinitis pigmentosa with late onset in addition to the lifelong night-blindness that would be expected from a lack of transducin function.
Conclusion: These data suggest that some truncating GNAT1 variants can indeed cause a recessive, mild, late-onset retinal degeneration in human beings rather than just stationary night-blindness as reported previously, with notable similarities to the phenotype of the Gnat1 knockout mouse.
Expanding the Mutation Spectrum for Inherited Retinal Diseases.
Lynn J, Huang S, Trigler G, Kingsley R, Coussa R, Bennett L Genes (Basel). 2025; 16(1).
PMID: 39858579 PMC: 11764958. DOI: 10.3390/genes16010032.
Missense mutations in CRX homeodomain cause dominant retinopathies through two distinct mechanisms.
Zheng Y, Sun C, Zhang X, Ruzycki P, Chen S Elife. 2023; 12.
PMID: 37963072 PMC: 10645426. DOI: 10.7554/eLife.87147.
The role of epigenetic methylation/demethylation in the regulation of retinal photoreceptors.
Lu C, Zhou Y, Zhang J, Su S, Liu Y, Peng G Front Cell Dev Biol. 2023; 11:1149132.
PMID: 37305686 PMC: 10251769. DOI: 10.3389/fcell.2023.1149132.
Berkowitz B, Podolsky R, Childers K, Roberts R, Katz R, Waseem R Invest Ophthalmol Vis Sci. 2022; 63(13):22.
PMID: 36576748 PMC: 9804021. DOI: 10.1167/iovs.63.13.22.
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.
Huang K, Zapata D, Tang Y, Teng Y, Li Y Biomaterials. 2022; 291:121876.
PMID: 36334354 PMC: 10018374. DOI: 10.1016/j.biomaterials.2022.121876.